Specifically, PD-1 immunotherapy response has been positively correlated to increasing tumor expression of PD-L1 (PD-1 ligand) and the number of tumor-infiltrating CD8+ T cells [2,11,12]. This evidence concerns the gene CD8A and neoplasm.